新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控

邓洁; 刘民; 刘珏

doi:10.16462/j.cnki.zhjbkz.2024.02.012

新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控

doi: 10.16462/j.cnki.zhjbkz.2024.02.012

北京大学公共卫生学院流行病与卫生统计学系，北京 100191

基金项目:

北京市自然科学基金-海淀原始创新联合基金 L222027

详细信息

通讯作者:
刘珏，E-mail：jueliu@bjmu.edu.cn

中图分类号: R373.1
计量
- 文章访问数: 50
- HTML全文浏览量: 17
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2023-02-17
- 修回日期: 2023-05-07
- 网络出版日期: 2024-03-30
- 刊出日期: 2024-02-10

Epidemiological feature and scientific prevention and control of SARS-CoV-2 Omicron subvariant XBB

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

Funds:

Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund L222027

More Information

Corresponding author: LIU Jue, E-mail: jueliu@bjmu.edu.cn

摘要

摘要: 目前新型冠状病毒感染仍处于全球大流行状态，Omicron变异株仍是全球优势株，在流行过程中不断进化和变异出现了许多新的亚型。XBB是由Omicron变异株BA.2.10.1和BA.2.75重组而成，于2022年8月在印度首次被发现，此后迅速传播并成为新加坡、马来西亚及一些欧美国家的主要流行株，并演变出XBB.1、XBB.1.5等亚分支。与Omicron变异株其他亚型相比，XBB的免疫逃逸能力显著增强，但目前尚无证据表明XBB感染所致的疾病严重程度与Omicron其他亚型有差异。建议加强病毒变异监测、开展重点人群疫苗加强针接种、加速疫苗和药物研发、开展多源监测动态评估风险，及时采取科学防控措施，减少XBB毒株的威胁。
- 新型冠状病毒 /
- Omicron变异株 /
- XBB /
- 流行特征 /
- 防控措施
Abstract: COVID-19 is still in the state of global pandemic currently. The Omicron variant is still the dominant strain worldwide, and many new subvariants have evolved and emerged continually during the pandemic. XBB is a recombinant of Omicron variants BA.2.10.1 and BA.2.75 sublineages, which was first identified in India in August 2022. Since then, it has rapidly spread to become the main epidemic variant in Singapore, Malaysia, as well as some European and American countries, and evolved some sublineages such as XBB.1, XBB.1.5, etc. XBB has a significantly increased immune escape ability compared with other circulating Omicron subvariants. But there is no evidence that the severity of XBB infection differs from other Omicron subvariants. It is recommended to strengthen the monitoring of virus mutation, carry out vaccination with booster doses in key populations, accelerate the research and development of vaccines and drugs, carry out multi-source monitoring to assess the risk dynamically, and timely take corresponding scientific prevention and control measures to reduce the threat of XBB strain.
- SARS-CoV-2 /
- Omicron variant /
- XBB /
- Epidemiological feature /
- Prevention and control measures

HTML全文

参考文献(39)

[1]	World Health Organization. WHO coronavirus (COVID-19) dashboard [EB/OL]. (2023-02-14) [2023-02-15]. https://covid19.who.int.
[2]	World Health Organization. Tracking SARS-CoV-2 variants [EB/OL]. (2023-01-04) [2023-01-04]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
[3]	World Health Organization. Weekly epidemiological update on COVID-19 - 8 February 2023 [EB/OL]. (2023-02-08) [2023-02-16]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-february-2023.
[4]	廖春晓, 王波, 吕筠, 等. 新型冠状病毒Omicron变异株病原学及流行病学研究进展[J]. 中华流行病学杂志, 2022, 43(11): 1691-1698. DOI: 10.3760/cma.j.cn112338-20220929-00829. Liao CX, Wang B, Lyu J, et al. Progress in research of etiology and epidemiology of 2019-nCoV Omicron variant [J]. Chin J Epidemiol, 2022, 43(11): 1691-1698. DOI: 10.3760/cma.j.cn112338-20220929-00829.
[5]	Singh P, Sharma K, Shaw D, et al. Mosaic recombination inflicted various SARS-CoV-2 lineages to emerge into novel virus variants: a review update [J]. Indian J Clin Biochem, 2022: 1-8. DOI: 10.1007/s12291-022-01109-w.
[6]	GISAID. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally over the past 6 months [EB/OL]. (2023-01-03) [2023-01-03]. https://gisaid.org/phylodynamics/global/nextstrain/.
[7]	World Health Organization. TAG-VE statement on Omicron sublineages BQ. 1 and XBB [EB/OL]. (2022-10-27) [2023-01-03]. https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-Omicron-sublineages-bq.1-and-xbb.
[8]	Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the Omicron subvariants BQ. 1.1 and XBB [J]. Lancet Infect Dis, 2023, 23(1): 30-32. DOI: 10.1016/S1473-3099(22)00816-7.
[9]	Wang Q, Iketani S, Li ZT, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants [J]. Cell, 2023, 186(2): 279-286. e8. DOI: 10.1016/j.cell.2022.12.018.
[10]	Wong C. Subvariant ′soup′ may drive wave [J]. New Sci, 2022, 256(3411): 11. DOI: 10.1016/s0262-4079(22)01970-4.
[11]	World Health Organization. Weekly epidemiological update on COVID-19 - 21 December 2022 [EB/OL]. (2022-12-21) [2023-01-03]. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update---21-december-2022.
[12]	World Health Organization. XBB. 1.5 updated rapid risk assessment, 25 January 2023 [EB/OL]. (2023-01-25) [2023-02-16]. https://www.who.int/docs/default-source/coronaviruse/25012023xbb.1.pdf?sfvrsn=c3956081_1.
[13]	American Centers for Disease Control and Prevention. COVID data tracker [EB/OL]. (2023-02-11) [2023-02-16] https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
[14]	American Centers for Disease Control and Prevention. COVID-19 data tracker weekly review [EB/OL]. (2023-01-02) [2023-01-03]. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/.
[15]	European Centre for Disease Prevention and Control. Country overview report: week 5 2023 [EB/OL]. (2023-02-09) [2023-02-16]. https://www.ecdc.europa.eu/en/covid-19/country-overviews?etrans=zh.
[16]	中华人民共和国国家卫生健康委员会宣传司. 国务院联防联控机制2022年12月20日新闻发布会文字实录[EB/OL]. (2022-12-20) [2023-01-03]. http://www.nhc.gov.cn/xcs/s3574/202212/a9510969ad85461297016f6ad1c87770.shtml.
[17]	环球网. 国内三地已监测到XBB毒株!有何症状?如何应对?重要提醒[EB/OL]. (2023-01-03) [2023-01-03]. https://baijiahao.baidu.com/s?id=1753956976992201683&wfr=spider&for=pc.
[18]	Outbreak. Info. SARS-CoV-2 (hCoV-19) mutation reports lineage comparison [EB/OL]. (2023-01-03) [2023-01-03]. https://outbreak.info/compare-lineages.
[19]	Scarpa F, Sanna D, Azzena I, et al. Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages [J]. J Med Virol, 2023, 95(3): e28625. DOI: 10.1002/jmv.28625.
[20]	Focosi D, McConnell S, Casadevall A. The Omicron variant of concern: diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies [J]. Drug Resist Updat, 2022, 65: 100882. DOI: 10.1016/j.drup.2022.100882.
[21]	Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ. 1.1 and XBB [J]. N Engl J Med, 2023, 388(1): 89-91. DOI: 10.1056/NEJMc2214302.
[22]	Cao YL, Jian FC, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution [J]. Nature, 2023, 614(7948): 521-529. DOI: 10.1038/s41586-022-05644-7.
[23]	Singapore Ministry of Health. Update on COVID-19 situation and measures to protect healthcare capacity [EB/OL]. (2022-10-15) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/update-on-covid-19-situation-and-measures-to-protect-healthcare-capacity.
[24]	Singapore Ministry of Health. Moh statement in response to XBB falsehoods [EB/OL]. (2022-10-11) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/moh-statement-in-response-to-xbb-falsehoods.
[25]	Singapore Ministry of Health. Opening remarks by minister for health mrongye kung at the moh press conference to update on the COVID-19 situation on 15 october 2022 [EB/OL]. (2022-10-15) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/opening-remarks-by-minister-for-health-mr-ong-ye-kung-at-the-moh-press-conference-to-update-on-the-covid-19-situation-on-15-october-2022.
[26]	Kurhade C, Zou J, Xia HJ, et al. Low neutralization of SARS-CoV-2 Omicron BA. 2.75.2, BQ. 1.1 and XBB. 1 by parental mRNA vaccine or a BA. 5 bivalent booster [J]. Nat Med, 2023, 29(2): 344-347. DOI: 10.1038/s41591-022-02162-x.
[27]	Zou J, Kurhade C, Patel S, et al. Improved neutralization of Omicron BA. 4/5, BA. 4.6, BA. 2.75.2, BQ. 1.1, and XBB. 1 with bivalent BA. 4/5 vaccine [J]. bioRxiv, 2022.11.17.516898. DOI: 10.1101/2022.11.17.516898.
[28]	Sullivan DJ, Franchini M, Senefeld JW, et al. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ. 1.1 and XBB. 1 [J]. J Gen Virol, 2023, 104(5): 001854. DOI: 10.1099/jgv.0.001854.
[29]	Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines [J]. J Med Virol, 2022, 94(5): 1825-1832. DOI: 10.1002/jmv.27588.
[30]	Callaway E. What Omicron′s BA. 4 and BA. 5 variants mean for the pandemic [J]. Nature, 2022, 606(7916): 848-849. DOI: 10.1038/d41586-022-01730-y.
[31]	中华人民共和国国家卫生健康委员会. 关于印发对新型冠状病毒感染实施"乙类乙管"总体方案的通知[EB/OL]. (2022-12-26) [2023-01-03]. http://www.nhc.gov.cn/xcs/zhengcwj/202212/e97e4c449d7a475794624b8ea12123c6.shtml.
[32]	Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial [J]. Lancet Infect Dis, 2022, 22(8): 1131-1141. DOI: 10.1016/S1473-3099(22)00271-7.
[33]	Romero-Ibarguengoitia ME, González-Cantú A, Rivera-Salinas D, et al. Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine in health workers in Mexico, a pilot study [J]. Vaccines (Basel), 2022, 10(7): 1139. DOI: 10.3390/vaccines10071139.
[34]	Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study [J]. BMJ, 2022, 379: e072141. DOI: 10.1136/bmj-2022-072141.
[35]	Intawong K, Chariyalertsak S, Chalom K, et al. Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and Omicron predominance in Thailand: a test-negative, case-control study [J]. Lancet Reg Health Southeast Asia, 2023, 10: 100121. DOI: 10.1016/j.lansea.2022.100121.
[36]	Kim YY, Choe YJ, Kim J, et al. Effectiveness of second mRNA COVID-19 booster vaccine in immunocompromised persons and long-term care facility residents [J]. Emerg Infect Dis, 2022, 28(11): 2165-2170. DOI: 10.3201/eid2811.220918.
[37]	Grewal R, Nguyen L, Buchan SA, et al. Effectiveness and duration of protection of a fourth dose of coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada [J]. J Infect Dis, 2023, 227(8): 977-980. DOI: 10.1093/infdis/jiac468.
[38]	Kislaya I, Machado A, Magalhães S, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA. 5 circulation: cohort study based on electronic health records, Portugal, May to July 2022 [J]. Eurosurveillance, 2022, 27(37). DOI: 10.2807/1560-7917.es.2022.27.37.2200697.
[39]	中国疾病预防控制中心. 关于XBB. 1.5毒株, 这些知识您需要了解[EB/OL]. (2023-01-04) [2023-02-15]. https://mp.weixin.qq.com/s/A11xGdJzhz4ERx9QxEDpow.